Phathom Pharmaceuticals Earnings & Forecasts

Phathom Pharmaceuticals (PHAT) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Jul 30, 2026	$0	$-0.11	100.0 %
Q1	Apr 30, 2026	$-0.18	$-0.21	14.3 %
Q4	Feb 26, 2026	$-0.08	$-0.19	57.9 %
Q3	Oct 30, 2025	$-0.15	$-0.41	63.4 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Jul 30, 2026	$74.30M	$73.55M	1.01 %
Q1	Apr 30, 2026	$58.30M	$56.79M	2.66 %
Q4	Feb 26, 2026	$57.58M	$57.43M	0.26 %
Q3	Oct 30, 2025	$49.50M	$47.87M	3.41 %

Phathom Pharmaceuticals Guidance

Phathom Pharmaceuticals (PHAT)는 7월 30, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $310M - $325M 범위로 예상했습니다.

이전 가이던스와 비교하여 Phathom Pharmaceuticals는 매출 전망치를 이전 범위인 하향 조정됨에서 $320M - $345M로 상향 조정했습니다.

Phathom Pharmaceuticals은 7과 8월 6, 2025 사이에 7월 30, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 3 times and lowered it 2 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$-0.11	$-0.21	$-0.19	$-0.41
Actual	$0.00	$-0.18	$-0.08	$-0.15
Surprise	+100.0%	+14.3%	+57.9%	+63.4%
Revenue
Estimate	$73.6M	$56.8M	$57.4M	$47.9M
Actual	$74.3M	$58.3M	$57.6M	$49.5M
Surprise	+1.01%	+2.66%	+0.26%	+3.41%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E
Earnings Per Share (Non-GAAP)
Consensus	$0.03	$0.10
Revenue
Consensus	$85.7M	$98.7M

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of $(0.79) per share

Benzinga Newsdesk

PRO
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est

Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.

Benzinga Newsdesk

Phathom Pharmaceuticals Inc